Newsroom | 5463 results

CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc. (the “Company”) today provided an update on its ongoing transition to a commercial‑stage company following the first anniversary of the FDA’s approval of ENCELTO™ (taroretcel-lwey), the Company’s encapsulated cell‑based gene therapy for adults with idiopathic Macular Telangiectasia Type 2 (MacTel). ENCELTO continues to be integrated into retina practices nationwide, supported by expanding access and established commercial manufa...

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients...

MIAMI--(BUSINESS WIRE)--Heru, the leader in AI-powered vision diagnostics, announced it is showcasing the new PretestPro on its Heru wearable platform at Vision Expo 2026....

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of Aurion Biotech’s medical advisory board (MAB). Dr. Farid is a distinguished cornea, cataract and refractive surgeon, a global e...

DURHAM, N,C.--(BUSINESS WIRE)--Sightview will showcase two recently updated tools for its eyecare-specific EHR/PM offering at Vision Expo 2026. See demos in booth #4021....

DULUTH, Ga.--(BUSINESS WIRE)--National Vision Announces Winners of 11th Annual Scholarship Program...

DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company developing first-in-class therapies for glaucoma, today announced the appointment of Fred Guerard, Pharm.D., as president and chief executive officer (CEO), effective March 1, 2026. He will also join the company’s Board of Directors. Dr. Guerard brings more than two decades of global leadership experience in ophthalmology and biotechnology, with a track record of advancing innovative therapies th...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D “Teach-in” webinar series that will provide deeper insights on the company’s differentiated product pipeline, which was unveiled in November 2025. On Monday, March 23, 2026, at 1:30 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hasha...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (« GenSight Biologics » ou la « Société ») (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique en phase clinique, spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et les troubles du système nerveux central, fait le point aujourd’hui sur les programmes d’accès précoce de GS010/LUMEVOQ® en cours ainsi que sur l’étu...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today provided updates on the GS010/LUMEVOQ® early access programs currently underway and the ongoing dose-ranging study REVISE. GS010/LUMEVOQ® is the Company’s candidate gene therapy in clinical development as a trea...